The Anagnostou Lab https://validator.w3.org/feed/docs/rss2.html The Anagnostou Lab is here! Home ctDNA residual disease may provide a molecular green light for perioperative immunotherapy in individuals with resectable mesothelioma. Bridging liquid biopsy discoveries with clinical cancer: Harnessing ctDNA Molecular Response to Predict Clinical Outcomes and Guide Therapeutic Decision Making for Individuals with Lung Cancer. Of Context, Quality, and Complexity: Fine-combing Tumor Mutational Burden in Immunotherapy-Treated Cancers Cancer evolution converging on common resistance mechanisms to PARP inhibition: A Molecular Tumor Board discussion. Can radiation help activate the immune system to fight cancer? How radioimmunotherapy affects immune response in patients with non-small cell lung cancer. 2025 Dedication of the Alex Grass Professor of Oncology Webinar on Early ctDNA Molecular Response Enhanced Through Integrated Analyses of Cell-Free DNA and Matched White Blood Cells. Hopkins Kimmel newsroom, video, “Capturing Immunotherapy Response in a Blood Drop” IASLC podcast on the Evolving Role of Liquid Biopsy for Lung Cancer (2023) Lab Members C3PO 2024 Postdoctoral Lecture Series Addressing Challenges in the Integration of Precision Oncology through Advances in Technology and Education Principal Investigator Publications Lab News Blog Johns Hopkins Kimmel Cancer Center Trainee Research Day 2024 Support Us Dual Insights in a Blood Draw: Cancer and Immune Cell Footprints in Blood Tests Capture Immunotherapy Outcomes and Toxicity for Patients with Lung Cancer. Research The revolutionary role of immunotherapy in the treatment of cancer Our team is headed to #AACR24! Awards Education Job Opportunities Contact Press releases People